Her Daughter Died After Taking a Generic Version of a Lifesaving Drug. This Is What She Wants You to Know.

BIAS: Lean Left
RELIABILITY: Very High

Political Bias Rating

This rating indicates the source’s editorial stance on the political spectrum, based on analysis from Media Bias/Fact Check, AllSides, and Ad Fontes Media.

Far Left / Left: Progressive editorial perspective
Lean Left: Slightly progressive tendency
Center: Balanced, minimal editorial slant
Lean Right: Slightly conservative tendency
Right / Far Right: Conservative editorial perspective

Current source: Lean Left. Stories with cross-spectrum coverage receive elevated prominence.

Reliability Rating

This rating measures the source’s factual accuracy, sourcing quality, and journalistic standards based on third-party fact-checking assessments.

Very High: Exceptional accuracy, rigorous sourcing
High: Strong factual reporting, minor issues rare
Mixed: Generally accurate but occasional concerns
Low: Frequent errors or misleading content
Very Low: Unreliable, significant factual issues

Current source: Very High. Higher reliability sources receive elevated weighting in story prioritization.

ProPublica
20:30Z

When I first learned that a critical medication for transplant patients — one that keeps them alive — had generic versions that might not be effective, I called a specialty pharmacist at a hospital in Virginia. Adam Cochrane had written a journal article about the problems with the generics. The drug is called tacrolimus, and it keeps a transplant patient’s body from rejecting a donated organ.

I was surprised to hear that Cochrane had several patients he thought had died in part because their generic tacrolimus hadn’t worked right. He told me about Hannah Goetz, though he didn’t divulge her name initially. She would become the focus of a story I published recently that’s part of a larger investigation into how the Food and Drug Administration has for years allowed risky drugs into your med

Continue reading at the original source

Read Full Article at ProPublica →